We characterized the fecal microbiota in a subset of anti-TNF-α refractory CD patients, patients with moderate to severe CD, who took part in a randomized, double-blind, placebo-controlled phase 2b clinical trial that demonstrated the efficacy of UST in treating CD (37). This evidence concerns the gene TNF and Cowden disease.